Adjuvant Tamoxifen in Breast Cancer Patients Affects the Endometrium by Time, an Effect Remaining Years after End of Treatment and Results in an Increased Frequency of Endometrial Carcinoma
Tamoxifen is the most used adjuvant drug in breast cancer treatment. Its main action is as an anti-oestrogen, but in the endometrium of some patients it acts as an oestrogen. Some investigators have even reported an increased risk of developing endometrial carcinoma. The question of how to follow-up...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2008-03, Vol.28 (2B), p.1259-1262 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1262 |
|---|---|
| container_issue | 2B |
| container_start_page | 1259 |
| container_title | Anticancer research |
| container_volume | 28 |
| creator | LINDAHL, Bengt ANDOLF, Ellika INGVAR, Christian RANSTAM, Jonas WILLEN, Roger |
| description | Tamoxifen is the most used adjuvant drug in breast cancer treatment. Its main action is as an anti-oestrogen, but in the endometrium
of some patients it acts as an oestrogen. Some investigators have even reported an increased risk of developing endometrial
carcinoma. The question of how to follow-up these patients and how to identify patients at risk of developing endometrial
premalignant changes was investigated by the non-invasive ultrasound method. The follow-up of 292 patients from before the
start of adjuvant treatment with tamoxifen and 94 without tamoxifen treatment was conducted at regular intervals. The changes
in endometrial thickness as measured by ultrasound and histopathological changes are reported. A thicker endometrium was found
in patients with receptor positive breast cancer even before the treatment with tamoxifen started. Cumulative increasing thickness
was found during treatment and this thicker endometrium remained until almost 3 years after the end of treatment. If the endometrium
was |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_564137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18505063</sourcerecordid><originalsourceid>FETCH-LOGICAL-h464t-9726f586b54436a26fac6415874a554082adf7f0bafb4c020f945c34372ba5803</originalsourceid><addsrcrecordid>eNp1ksFu0zAYgCMEYmXwCsgXOC2S49iJfexKB5MqgVBB4mT9cezWI3GKnWz04Xg3_tKunHaw7Fjf9_05-Fk2K2pV5LUo6fNsRpmgeU2puMhepXRHaVUpWb7MLgopqKBVOcv-zNu76R7CSNbQD7-9s4H4QK6jhTSSBQRjI_kCo7dhTGTunDW4j1tLlqEdejtGP_Wk2ZO17-0VgUCW_xjy1fbggw8b8sNCTATciCWUyODIGvNjj0kUWkTT1GEV56J_G8xhuG3JTbS_JhvM_qCcx0GHvxWND0MPr7MXDrpk35z2y-zbzXK9-JSvPn-8XcxX-ZZXfMxVzSonZNUIzssK8ANMxQshaw5CcCoZtK52tAHXcEMZdYoLU_KyZg0IScvLLD9204PdTY3eRd9D3OsBvD5d_cST1QKzZY28epLfxaH9Lz2KRVEpWstKobt60u2mHa4G18FplaltQ1ttKbWaK5BaNS3VBeUcCuMaYwrMXT2Z--C_z_UQN3qadMGEZAf87RFHtrftGX98MQi8OwGQDHQu4hPx6cwxyqRSUiL3_sht_Wb74KPVqYeuw2ypITKp2fVhpir_Agzc27s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adjuvant Tamoxifen in Breast Cancer Patients Affects the Endometrium by Time, an Effect Remaining Years after End of Treatment and Results in an Increased Frequency of Endometrial Carcinoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>LINDAHL, Bengt ; ANDOLF, Ellika ; INGVAR, Christian ; RANSTAM, Jonas ; WILLEN, Roger</creator><creatorcontrib>LINDAHL, Bengt ; ANDOLF, Ellika ; INGVAR, Christian ; RANSTAM, Jonas ; WILLEN, Roger</creatorcontrib><description>Tamoxifen is the most used adjuvant drug in breast cancer treatment. Its main action is as an anti-oestrogen, but in the endometrium
of some patients it acts as an oestrogen. Some investigators have even reported an increased risk of developing endometrial
carcinoma. The question of how to follow-up these patients and how to identify patients at risk of developing endometrial
premalignant changes was investigated by the non-invasive ultrasound method. The follow-up of 292 patients from before the
start of adjuvant treatment with tamoxifen and 94 without tamoxifen treatment was conducted at regular intervals. The changes
in endometrial thickness as measured by ultrasound and histopathological changes are reported. A thicker endometrium was found
in patients with receptor positive breast cancer even before the treatment with tamoxifen started. Cumulative increasing thickness
was found during treatment and this thicker endometrium remained until almost 3 years after the end of treatment. If the endometrium
was <3 mm after 3 months of treatment the probability that it would be thin after 5 years was high. An increased risk of developing
endometrial carcinoma was found, however due to this regular follow-up the cancer was identified at an early stage.</description><identifier>ISSN: 0250-7005</identifier><identifier>ISSN: 1791-7530</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 18505063</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Biological and medical sciences ; Breast Neoplasms - drug therapy ; breat cancer ; Cancer and Oncology ; Cancer och onkologi ; Chemotherapy, Adjuvant ; Clinical Medicine ; endometiral carcinoma ; Endometrial Neoplasms - chemically induced ; Endometrial Neoplasms - pathology ; Endometrium - diagnostic imaging ; Endometrium - drug effects ; Endometrium - pathology ; Female ; Follow-Up Studies ; Gynecology. Andrology. Obstetrics ; Humans ; Kirurgi ; Klinisk medicin ; Mammary gland diseases ; Medical and Health Sciences ; Medical sciences ; MEDICIN ; Medicin och hälsovetenskap ; MEDICINE ; Middle Aged ; Morfologi, cellbiologi, patologi ; Morphology, cell biology, pathology ; Obstetrics and gynaecology ; Obstetrics and women's diseases ; Obstetrik och gynekologi ; Obstetrik och kvinnosjukdomar ; Pathology ; Patologi ; Surgery ; Tamofixen ; Tamoxifen - administration & dosage ; Tamoxifen - adverse effects ; Tumors ; Ultrasonography</subject><ispartof>Anticancer research, 2008-03, Vol.28 (2B), p.1259-1262</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20289988$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18505063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-125821$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/1153729$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:116907869$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>LINDAHL, Bengt</creatorcontrib><creatorcontrib>ANDOLF, Ellika</creatorcontrib><creatorcontrib>INGVAR, Christian</creatorcontrib><creatorcontrib>RANSTAM, Jonas</creatorcontrib><creatorcontrib>WILLEN, Roger</creatorcontrib><title>Adjuvant Tamoxifen in Breast Cancer Patients Affects the Endometrium by Time, an Effect Remaining Years after End of Treatment and Results in an Increased Frequency of Endometrial Carcinoma</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Tamoxifen is the most used adjuvant drug in breast cancer treatment. Its main action is as an anti-oestrogen, but in the endometrium
of some patients it acts as an oestrogen. Some investigators have even reported an increased risk of developing endometrial
carcinoma. The question of how to follow-up these patients and how to identify patients at risk of developing endometrial
premalignant changes was investigated by the non-invasive ultrasound method. The follow-up of 292 patients from before the
start of adjuvant treatment with tamoxifen and 94 without tamoxifen treatment was conducted at regular intervals. The changes
in endometrial thickness as measured by ultrasound and histopathological changes are reported. A thicker endometrium was found
in patients with receptor positive breast cancer even before the treatment with tamoxifen started. Cumulative increasing thickness
was found during treatment and this thicker endometrium remained until almost 3 years after the end of treatment. If the endometrium
was <3 mm after 3 months of treatment the probability that it would be thin after 5 years was high. An increased risk of developing
endometrial carcinoma was found, however due to this regular follow-up the cancer was identified at an early stage.</description><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>breat cancer</subject><subject>Cancer and Oncology</subject><subject>Cancer och onkologi</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical Medicine</subject><subject>endometiral carcinoma</subject><subject>Endometrial Neoplasms - chemically induced</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Endometrium - diagnostic imaging</subject><subject>Endometrium - drug effects</subject><subject>Endometrium - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Kirurgi</subject><subject>Klinisk medicin</subject><subject>Mammary gland diseases</subject><subject>Medical and Health Sciences</subject><subject>Medical sciences</subject><subject>MEDICIN</subject><subject>Medicin och hälsovetenskap</subject><subject>MEDICINE</subject><subject>Middle Aged</subject><subject>Morfologi, cellbiologi, patologi</subject><subject>Morphology, cell biology, pathology</subject><subject>Obstetrics and gynaecology</subject><subject>Obstetrics and women's diseases</subject><subject>Obstetrik och gynekologi</subject><subject>Obstetrik och kvinnosjukdomar</subject><subject>Pathology</subject><subject>Patologi</subject><subject>Surgery</subject><subject>Tamofixen</subject><subject>Tamoxifen - administration & dosage</subject><subject>Tamoxifen - adverse effects</subject><subject>Tumors</subject><subject>Ultrasonography</subject><issn>0250-7005</issn><issn>1791-7530</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ksFu0zAYgCMEYmXwCsgXOC2S49iJfexKB5MqgVBB4mT9cezWI3GKnWz04Xg3_tKunHaw7Fjf9_05-Fk2K2pV5LUo6fNsRpmgeU2puMhepXRHaVUpWb7MLgopqKBVOcv-zNu76R7CSNbQD7-9s4H4QK6jhTSSBQRjI_kCo7dhTGTunDW4j1tLlqEdejtGP_Wk2ZO17-0VgUCW_xjy1fbggw8b8sNCTATciCWUyODIGvNjj0kUWkTT1GEV56J_G8xhuG3JTbS_JhvM_qCcx0GHvxWND0MPr7MXDrpk35z2y-zbzXK9-JSvPn-8XcxX-ZZXfMxVzSonZNUIzssK8ANMxQshaw5CcCoZtK52tAHXcEMZdYoLU_KyZg0IScvLLD9204PdTY3eRd9D3OsBvD5d_cST1QKzZY28epLfxaH9Lz2KRVEpWstKobt60u2mHa4G18FplaltQ1ttKbWaK5BaNS3VBeUcCuMaYwrMXT2Z--C_z_UQN3qadMGEZAf87RFHtrftGX98MQi8OwGQDHQu4hPx6cwxyqRSUiL3_sht_Wb74KPVqYeuw2ypITKp2fVhpir_Agzc27s</recordid><startdate>20080301</startdate><enddate>20080301</enddate><creator>LINDAHL, Bengt</creator><creator>ANDOLF, Ellika</creator><creator>INGVAR, Christian</creator><creator>RANSTAM, Jonas</creator><creator>WILLEN, Roger</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF2</scope><scope>D95</scope></search><sort><creationdate>20080301</creationdate><title>Adjuvant Tamoxifen in Breast Cancer Patients Affects the Endometrium by Time, an Effect Remaining Years after End of Treatment and Results in an Increased Frequency of Endometrial Carcinoma</title><author>LINDAHL, Bengt ; ANDOLF, Ellika ; INGVAR, Christian ; RANSTAM, Jonas ; WILLEN, Roger</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h464t-9726f586b54436a26fac6415874a554082adf7f0bafb4c020f945c34372ba5803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>breat cancer</topic><topic>Cancer and Oncology</topic><topic>Cancer och onkologi</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical Medicine</topic><topic>endometiral carcinoma</topic><topic>Endometrial Neoplasms - chemically induced</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Endometrium - diagnostic imaging</topic><topic>Endometrium - drug effects</topic><topic>Endometrium - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Kirurgi</topic><topic>Klinisk medicin</topic><topic>Mammary gland diseases</topic><topic>Medical and Health Sciences</topic><topic>Medical sciences</topic><topic>MEDICIN</topic><topic>Medicin och hälsovetenskap</topic><topic>MEDICINE</topic><topic>Middle Aged</topic><topic>Morfologi, cellbiologi, patologi</topic><topic>Morphology, cell biology, pathology</topic><topic>Obstetrics and gynaecology</topic><topic>Obstetrics and women's diseases</topic><topic>Obstetrik och gynekologi</topic><topic>Obstetrik och kvinnosjukdomar</topic><topic>Pathology</topic><topic>Patologi</topic><topic>Surgery</topic><topic>Tamofixen</topic><topic>Tamoxifen - administration & dosage</topic><topic>Tamoxifen - adverse effects</topic><topic>Tumors</topic><topic>Ultrasonography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LINDAHL, Bengt</creatorcontrib><creatorcontrib>ANDOLF, Ellika</creatorcontrib><creatorcontrib>INGVAR, Christian</creatorcontrib><creatorcontrib>RANSTAM, Jonas</creatorcontrib><creatorcontrib>WILLEN, Roger</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Uppsala universitet</collection><collection>SWEPUB Lunds universitet</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LINDAHL, Bengt</au><au>ANDOLF, Ellika</au><au>INGVAR, Christian</au><au>RANSTAM, Jonas</au><au>WILLEN, Roger</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant Tamoxifen in Breast Cancer Patients Affects the Endometrium by Time, an Effect Remaining Years after End of Treatment and Results in an Increased Frequency of Endometrial Carcinoma</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2008-03-01</date><risdate>2008</risdate><volume>28</volume><issue>2B</issue><spage>1259</spage><epage>1262</epage><pages>1259-1262</pages><issn>0250-7005</issn><issn>1791-7530</issn><eissn>1791-7530</eissn><abstract>Tamoxifen is the most used adjuvant drug in breast cancer treatment. Its main action is as an anti-oestrogen, but in the endometrium
of some patients it acts as an oestrogen. Some investigators have even reported an increased risk of developing endometrial
carcinoma. The question of how to follow-up these patients and how to identify patients at risk of developing endometrial
premalignant changes was investigated by the non-invasive ultrasound method. The follow-up of 292 patients from before the
start of adjuvant treatment with tamoxifen and 94 without tamoxifen treatment was conducted at regular intervals. The changes
in endometrial thickness as measured by ultrasound and histopathological changes are reported. A thicker endometrium was found
in patients with receptor positive breast cancer even before the treatment with tamoxifen started. Cumulative increasing thickness
was found during treatment and this thicker endometrium remained until almost 3 years after the end of treatment. If the endometrium
was <3 mm after 3 months of treatment the probability that it would be thin after 5 years was high. An increased risk of developing
endometrial carcinoma was found, however due to this regular follow-up the cancer was identified at an early stage.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>18505063</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2008-03, Vol.28 (2B), p.1259-1262 |
| issn | 0250-7005 1791-7530 1791-7530 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_564137 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Biological and medical sciences Breast Neoplasms - drug therapy breat cancer Cancer and Oncology Cancer och onkologi Chemotherapy, Adjuvant Clinical Medicine endometiral carcinoma Endometrial Neoplasms - chemically induced Endometrial Neoplasms - pathology Endometrium - diagnostic imaging Endometrium - drug effects Endometrium - pathology Female Follow-Up Studies Gynecology. Andrology. Obstetrics Humans Kirurgi Klinisk medicin Mammary gland diseases Medical and Health Sciences Medical sciences MEDICIN Medicin och hälsovetenskap MEDICINE Middle Aged Morfologi, cellbiologi, patologi Morphology, cell biology, pathology Obstetrics and gynaecology Obstetrics and women's diseases Obstetrik och gynekologi Obstetrik och kvinnosjukdomar Pathology Patologi Surgery Tamofixen Tamoxifen - administration & dosage Tamoxifen - adverse effects Tumors Ultrasonography |
| title | Adjuvant Tamoxifen in Breast Cancer Patients Affects the Endometrium by Time, an Effect Remaining Years after End of Treatment and Results in an Increased Frequency of Endometrial Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T20%3A55%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20Tamoxifen%20in%20Breast%20Cancer%20Patients%20Affects%20the%20Endometrium%20by%20Time,%20an%20Effect%20Remaining%20Years%20after%20End%20of%20Treatment%20and%20Results%20in%20an%20Increased%20Frequency%20of%20Endometrial%20Carcinoma&rft.jtitle=Anticancer%20research&rft.au=LINDAHL,%20Bengt&rft.date=2008-03-01&rft.volume=28&rft.issue=2B&rft.spage=1259&rft.epage=1262&rft.pages=1259-1262&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cpubmed_swepu%3E18505063%3C/pubmed_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18505063&rfr_iscdi=true |